{
    "nct_id": "NCT04838613",
    "official_title": "Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]",
    "inclusion_criteria": "Healthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Inability to complete the needed investigational and standard-of-care imaging examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)\n* Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID-19\n* Prior major surgery undergone less than 12 weeks prior to screening (with the exception of any surgery related to prostatic cancer)\n* Known allergy, hypersensitivity, or intolerance to [18F]CTT1057, [68Ga]Ga-PSMA-11, or to CT contrast\n* Prior and current use of PSMA targeted therapies\n* Prior ADT (first or second generation), including LHRH analogues (agonists or antagonists), within 9 months before screening\n* Any 5-alpha reductase inhibitors within 30 days before screening\n* Use of other investigational drugs within 30 days before screening\n* Castration-resistant patients\n* Patient with small cell or neuroendocrine PCa in more than 50% of biopsy tissue\n* Prior salvage surgery or salvage radiation therapy",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Signed informed consent must be obtained prior to participation in the study\n* Biopsy proven prostate adenocarcinoma.\n* Biochemical recurrence following initial definitive therapy (with either RP or curative intent radiation therapy) as defined:\n\nby AUA criteria (Cookson et al 2007) for patients who have undergone RP: Initial serum PSA of ≥0.2 ng/ml measured at least 6 weeks after RP with a second confirmatory persistent PSA level of >0.2 ng/ml, or by ASTRO-Phoenix criteria (Roach et al 2006) for patients who have undergone curative-intent radiation therapy (RT): Rise of serum PSA measurement of 2 or more ng/mL above the nadir PSA observed post RT.\n\n* ECOG performance status 0-2\n* Participants must be adults ≥ 18 years of age"
}